We’re a pre-seed startup founded by three PhD students from Israel(Technion, Bar-Ilan, Haifa Uni.), joined by the former Director of Business Development at IBM Watson Health and a seasoned product engineer.

Motivated by personal ties to chronic illness, we aim to revolutionize drug development by harnessing the human microbiome—boosting drug efficacy from 40% to 60–80%, halving trial timelines, and becoming the foundational tech for microbiome-based clinical development.Our AI-powered SaaS platform translates microbiome, genomic, and clinical data into actionable tools for precision drug development.

Validated in discussions with Merck, Novo Nordisk, Teva, and Servier, we’ve aligned our roadmap with pharma’s biggest unmet needs, targeting a $4.6B market by 2030.We’ve already built a proprietary database of 63,000 patient samples, complete with in-house bioinformatics pipelines, custom quality metrics, and secure AWS hosting.

Our colorectal cancer proof-of-concept achieves 90% accuracy, reduces non-responder recruitment by 35%, and surfaces novel, explainable biomarkers to enhance trial efficiency and patient outcomes.Advisory Board:1) Dr.

Milena Pitashny: Head of Clinical and Research Microbiome Center, Rambam Health Care Campus. 2)Prof.

Naama Geva-Zatorsky Principal Investigator, Gut Microbiota – Host Interactions.

Technion - Israel Institute of Technology.